ATIM-24. TARGETING MYELOID DERIVED SUPPRESSOR CELLS: PHASE 0/1 TRIAL OF LOW DOSE CAPECITABINE + BEVACIZUMAB IN PATIENTS WITH RECURRENT GLIOBLASTOMA

BACKGROUND: Glioblastoma creates an immunosuppressive environment that allows tumor growth. Myeloid derived suppressor cells (MDSCs), a class of immunosuppressive cells, mediate immunosuppression in GBMs. MDSCs are up-regulated in the blood of GBM patients. We have developed a novel strategy to targ...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Neuro Oncol
Auteurs principaux: Peereboom, David M, Vogelbaum, Michael, Mohammadi, Alireza, Alban, Tyler, Brewer, Cathy, Ahluwalia, Manmeet, Sinyuk, Maksim, Lathia, Justin
Format: Artigo
Langue:Inglês
Publié: Oxford University Press 2017
Sujets:
Abstracts
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC5692853/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/nox168.119
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires